Dangerfield W - Search Results

1

Studies on quinazolinones as dual inhibitors of Pgp and MRP1 in multidrug resistance.

Wang S, Ryder H, Pretswell I, Depledge P, Milton J, Hancox TC, Dale I, Dangerfield W, Charlton P, Faint R, Dodd R, Hassan S. Wang S, et al. Among authors: dangerfield w. Bioorg Med Chem Lett. 2002 Feb 25;12(4):571-4. doi: 10.1016/s0960-894x(01)00804-6. Bioorg Med Chem Lett. 2002. PMID: 11844674

2

Novel angular benzophenazines: dual topoisomerase I and topoisomerase II inhibitors as potential anticancer agents.

Vicker N, Burgess L, Chuckowree IS, Dodd R, Folkes AJ, Hardick DJ, Hancox TC, Miller W, Milton J, Sohal S, Wang S, Wren SP, Charlton PA, Dangerfield W, Liddle C, Mistry P, Stewart AJ, Denny WA. Vicker N, et al. Among authors: dangerfield w. J Med Chem. 2002 Jan 31;45(3):721-39. doi: 10.1021/jm010329a. J Med Chem. 2002. PMID: 11806724

3

Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives.

Roe M, Folkes A, Ashworth P, Brumwell J, Chima L, Hunjan S, Pretswell I, Dangerfield W, Ryder H, Charlton P. Roe M, et al. Among authors: dangerfield w. Bioorg Med Chem Lett. 1999 Feb 22;9(4):595-600. doi: 10.1016/s0960-894x(99)00030-x. Bioorg Med Chem Lett. 1999. PMID: 10098671

4

Structure-activity relationships for pyrido-, imidazo-, pyrazolo-, pyrazino-, and pyrrolophenazinecarboxamides as topoisomerase-targeted anticancer agents.

Gamage SA, Spicer JA, Rewcastle GW, Milton J, Sohal S, Dangerfield W, Mistry P, Vicker N, Charlton PA, Denny WA. Gamage SA, et al. Among authors: dangerfield w. J Med Chem. 2002 Jan 31;45(3):740-3. doi: 10.1021/jm010330+. J Med Chem. 2002. PMID: 11806725

5

In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.

Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, Bootle D, Plumb JA, Templeton D, Charlton P. Mistry P, et al. Among authors: dangerfield w. Cancer Res. 2001 Jan 15;61(2):749-58. Cancer Res. 2001. PMID: 11212278

6

In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II.

Mistry P, Stewart AJ, Dangerfield W, Baker M, Liddle C, Bootle D, Kofler B, Laurie D, Denny WA, Baguley B, Charlton PA. Mistry P, et al. Among authors: dangerfield w. Anticancer Drugs. 2002 Jan;13(1):15-28. doi: 10.1097/00001813-200201000-00002. Anticancer Drugs. 2002. PMID: 11914637

7

Antitumor activity of XR5944, a novel and potent topoisomerase poison.

Stewart AJ, Mistry P, Dangerfield W, Bootle D, Baker M, Kofler B, Okiji S, Baguley BC, Denny WA, Charlton PA. Stewart AJ, et al. Among authors: dangerfield w. Anticancer Drugs. 2001 Apr;12(4):359-67. doi: 10.1097/00001813-200104000-00009. Anticancer Drugs. 2001. PMID: 11335793

8

Serum lipoproteins and atherosclerosis in animals.

Dangerfield WG, Finlayson R, Myatt G, Mead MG. Dangerfield WG, et al. Atherosclerosis. 1976 Oct;25(1):95-106. doi: 10.1016/0021-9150(76)90051-4. Atherosclerosis. 1976. PMID: 186081

9

The investigation of "mid-band" lipoproteins using polyacrylamide gel electrophoresis.

Mead MG, Dangerfield WG. Mead MG, et al. Among authors: dangerfield wg. Clin Chim Acta. 1974 Mar 15;51(2):173-82. doi: 10.1016/0009-8981(74)90027-8. Clin Chim Acta. 1974. PMID: 4133339 No abstract available.

10

Electrophoresis of plasma lipoproteins.

Dangerfield WG, Tarlow D. Dangerfield WG, et al. Proc R Soc Med. 1971 Sep;64(9):896-9. Proc R Soc Med. 1971. PMID: 5114284 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

26 results

Search Page

Filters